Sandoz presents compelling investment proposition as standalone company at Capital Markets Day
08 juin 2023 01h15 HE
|
Novartis Pharma AG
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to further...
Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
09 mai 2023 15h00 HE
|
Novartis Pharma AG
Sandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansion Sandoz gains access to proprietary AI-driven technology platform...
Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines
04 mai 2023 01h15 HE
|
Novartis Pharma AG
Agreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology. Products from Adalvo slated for near- to mid-term launches, with four out of six...
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
03 avr. 2023 07h33 HE
|
Novartis Pharma AG
Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers...
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
21 mars 2023 10h48 HE
|
Novartis Pharma AG
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer...
Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten
25 août 2022 01h00 HE
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Die strategische Überprüfung von Sandoz hat ergeben, dass eine Abspaltung von Sandoz durch eine hundertprozentige Ausgliederung im besten Interesse der...
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
25 août 2022 01h00 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1...
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
21 juil. 2022 01h15 HE
|
Novartis Pharma AG
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic...
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
22 juin 2022 20h01 HE
|
Novartis Pharma AG
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD...
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
31 mai 2022 01h15 HE
|
Novartis Pharma AG
Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap...